Olive Leaf Extracts in the Control of Diabet

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

Also called NCT05605704

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05605704
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Tunisia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05605704. Randomized; single masking; primary purpose prevention. Start 2023-01-01 (actual); primary completion 2025-09-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Olive Leaf Extracts in the Control of Diabet
Acronym
Dia-Athr
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Atherolive
Intervention (Drug)
Placebo Atherolive
Lead sponsor
University of Monastir (class: other)

Record details

Record id
cardio:ct-nct05605704
Content hash
1cd0d1fc3efec0b64167a782ed7dfba1d0ab1010fada159fa1914b2890177fb3